Clinical trial / 2006
Curcumin reduced relapse rates and improved clinical measures in quiescent ulcerative colitis.
In a randomized trial of 89 participants with quiescent ulcerative colitis, participants received 2 g daily of curcumin or placebo alongside standard therapy for 6 months. Among per-protocol participants, 4.65% (2 of 43) in the curcumin group relapsed compared to 20.51% (8 of 39) in the placebo group (P = 0.040; intention-to-treat P = 0.049). Curcumin also significantly improved both the clinical activity index (P = 0.038) and the endoscopic index (P = 0.0001).
- Study type
- Randomized controlled trial
- Who was studied
- 89 patients with quiescent ulcerative colitis
- What was measured
- Relapse rate and endoscopic/clinical indices at 6 months
THE PAPER
Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial.
Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, Tsujikawa T, Fujiyama Y, Mitsuyama K, Sata M, Yamada M, Iwaoka Y, Kanke K, Hiraishi H, Hirayama K, Arai H, Yoshii S, Uchijima M, Nagata T, Koide Y. Clin Gastroenterol Hepatol, 2006.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.